Immunogenicity and Safety of a Candidate Tuberculosis (TB) Vaccine Given to Healthy Adults in a TB-endemic Region

Inclusion Criteria: * Subjects who the Investigator believes that they can and will comply with the requirements of the protocol. * A male or female between, and including, 21 and 40 years of age at the time of the first vaccination. * Written informed consent obtained from the subject prior to any study procedure. * Free of obvious health problems as established by medical history and clinical examination before enrolment into the study. * If the subject is female, she must be of non-childbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination, have a negative pregnancy test and continue such precautions for 2 months after completion of the vaccination series. * No evidence of pulmonary pathology as confirmed by chest X-ray. * Clinically normal laboratory values for creatinine, ALT, AST and complete blood count. * Seronegative for human immunodeficiency virus-1 (HIV-1). * No history of extrapulmonary TB. * Subjects must have the appropriate PPD skin reactivity (induration measured at 48 to 72 hours after PPD skin test administration). Exclusion Criteria: * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of vaccine, or planned use during the study period. * Chronic administration of immunosuppressants or other immune-modifying drugs within 6 months prior to the first vaccine dose. * History of previous administration of experimental Mycobacterium tuberculosis vaccines. * History of previous exposure to experimental products containing MPL or QS21. * Administration of any immunoglobulins, any immunotherapy and/or any blood products within the three months preceding the first dose of study vaccination, or planned administrations during the study period. * Participation in another experimental protocol during the study period. * Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination. * A family history of congenital or hereditary immunodeficiency. Subjects who describe a first-degree relative with clearly documented autoimmune disease will be excluded * History of any acute or chronic illness or medication that, in the opinion of the Investigator, may interfere with the evaluation of the safety or immunogenicity of the vaccine. * Any chronic drug therapy to be continued during the study period, with the exception of vitamins and/or dietary supplements, birth control pills, anti-histamines for seasonal allergies, SSRIs. * History of any neurologic disorders or seizures. * History of allergic reactions or anaphylaxis to previous immunisations. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * History of chronic alcohol consumption and/or drug abuse which in the investigators opinion would put the subject at risk. * Major congenital defects. * Pregnant or lactating female. * Female planning to become pregnant or planning to discontinue contraceptive precautions.